{
    "clinical_study": {
        "@rank": "38689", 
        "arm_group": {
            "arm_group_label": "LJM716+cetuximab", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "To establish whether LJM716 in combination with cetuximab is safe and has beneficial effects\n      in patients with platinum-pretreated recurrent/metastatic head and neck squamous cell\n      carcinoma."
        }, 
        "brief_title": "Study of Efficacy and Safety of LJM716 and Cetuximab in Head and Neck Squamous Cell Carcinoma Patients", 
        "completion_date": {
            "#text": "December 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Head and Neck Squamous Cell Carcinoma", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma", 
                "Carcinoma, Squamous Cell", 
                "Head and Neck Neoplasms"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Most recent regimen contains both platinum and cetuximab (Phase II, group B).\n\n          -  ECOG Performance Status (PS) \u2264 2.\n\n          -  Recovery from all AEs of previous anti-cancer therapies, to baseline or to CTCAE\n             Grade \u2264 1, except for alopecia.\n\n          -  Measurable disease as determined by RECIST v1.1.\n\n        Exclusion Criteria:\n\n          -  Previous anti-HER3 antibody treatment.\n\n          -  Symptomatic brain metastasis.\n\n          -  Prior systemic anti-cancer treatment, within a period of time that is shorter than\n             the cycle length used for that treatment prior to starting study treatment.\n\n          -  Prior anaphylactic or other severe infusion reaction to human immunoglobulin or\n             antibody formulations.\n\n          -  Inadequate end organ function.\n\n          -  Ongoing diarrhea CTCAE Grade \u2265 2. Other protocol-defined inclusion/exclusion criteria\n             may apply"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "128", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 19, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02143622", 
            "org_study_id": "CLJM716X2104"
        }, 
        "intervention": [
            {
                "arm_group_label": "LJM716+cetuximab", 
                "description": "antibody", 
                "intervention_name": "LJM716", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "LJM716+cetuximab", 
                "description": "antibody", 
                "intervention_name": "cetuximab", 
                "intervention_type": "Biological"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Cetuximab"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": "Head and neck cancer", 
        "lastchanged_date": "May 21, 2014", 
        "location": [
            {
                "contact": {
                    "email": "Ruggiero.vincent@mayo.edu", 
                    "last_name": "Vincent Ruggiero", 
                    "phone": "480-342-3256"
                }, 
                "facility": {
                    "address": {
                        "city": "Scottsdale", 
                        "country": "United States", 
                        "state": "Arizona"
                    }, 
                    "name": "Mayo Clinic - Arizona Dept of Oncology"
                }, 
                "investigator": {
                    "last_name": "Kelly K. Curtis", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "Geraldine.tomassi@yale.edu", 
                    "last_name": "Jerri Tomassi", 
                    "phone": "203-737-8367"
                }, 
                "facility": {
                    "address": {
                        "city": "New Haven", 
                        "country": "United States", 
                        "state": "Connecticut", 
                        "zip": "06520"
                    }, 
                    "name": "Yale University School of Medicine Onc Dept"
                }, 
                "investigator": {
                    "last_name": "Barbara Burtness", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "craines1@jhmi.edu", 
                    "last_name": "Charles Raines", 
                    "phone": "410-502-0678"
                }, 
                "facility": {
                    "address": {
                        "city": "Baltimore", 
                        "country": "United States", 
                        "state": "Maryland", 
                        "zip": "21231"
                    }, 
                    "name": "Sidney Kimmel Comprehensive Cancer Center/Johns Hopkins Med. Dept. of Onc."
                }, 
                "investigator": {
                    "last_name": "Christine Chung", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "miestes@med.umich.edu", 
                    "last_name": "Suzanne Miesterfeld", 
                    "phone": "+1 734 232 0753"
                }, 
                "facility": {
                    "address": {
                        "city": "Ann Arbor", 
                        "country": "United States", 
                        "state": "Michigan", 
                        "zip": "48109-0944"
                    }, 
                    "name": "University of Michigan Comprehensive Cancer Center Onc Dept."
                }, 
                "investigator": {
                    "last_name": "Francis Paul Worden", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "keith.salador@fccc.edu", 
                    "last_name": "Keith Salador", 
                    "phone": "215-214-4297"
                }, 
                "facility": {
                    "address": {
                        "city": "Philadelphia", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "19111-2497"
                    }, 
                    "name": "Fox Chase Cancer Center Fox Chase Cancer (2)"
                }, 
                "investigator": {
                    "last_name": "Ranee Mehra", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "Regulatoryaffairs@uthscsa.edu", 
                    "last_name": "Lisa Creighton", 
                    "phone": "210-450-1789"
                }, 
                "facility": {
                    "address": {
                        "city": "San Antonio", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "78229"
                    }, 
                    "name": "Cancer Therapy & Research Center / UT Health Science Center Onc. Dept."
                }, 
                "investigator": {
                    "last_name": "Ahmad Wehbe", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Toronto", 
                        "country": "Canada", 
                        "state": "Ontario", 
                        "zip": "M5G 2M9"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Ancona", 
                        "country": "Italy", 
                        "state": "AN", 
                        "zip": "60126"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Milano", 
                        "country": "Italy", 
                        "state": "MI", 
                        "zip": "20133"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Singapore", 
                        "country": "Singapore", 
                        "zip": "119228"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Barcelona", 
                        "country": "Spain", 
                        "state": "Catalunya", 
                        "zip": "08036"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Madrid", 
                        "country": "Spain", 
                        "zip": "28041"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "St. Gallen", 
                        "country": "Switzerland", 
                        "zip": "9007"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Canada", 
                "Italy", 
                "Singapore", 
                "Spain", 
                "Switzerland"
            ]
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase Ib/II, Multicenter Study of LJM716 in Combination With Cetuximab in Patients With Platinum-pretreated Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma", 
        "overall_contact": {
            "last_name": "Novartis Pharmaceuticals", 
            "phone": "1-888-669-6682"
        }, 
        "overall_contact_backup": {
            "last_name": "Novartis Pharmaceuticals", 
            "phone_ext": "+41613241111"
        }, 
        "overall_official": {
            "affiliation": "Novartis Pharmaceuticals", 
            "last_name": "Novartis Pharmaceuticals", 
            "role": "Study Director"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": [
                "Germany: Federal Institute for Drugs and Medical Devices (BfArM)", 
                "Canada: Health Canada", 
                "France: National Agency for the Safety of Medicines and Health Products (MSNA)", 
                "Spain: Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios", 
                "Singapore: Health Sciences Authority", 
                "Switzerland: Swissmedic", 
                "Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)", 
                "Italy: The Italian Medicines Agency", 
                "United States: Food and Drug Administration"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "December 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Assessment of the preliminary anti-tumor activity of LJM716 in combination. Change in target lesion measurements, from baseline as per RECIST 1.1", 
                "measure": "Phase Ib: Target lesion change compared to baseline in patients, per RECIST 1.1", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "description": "The dose escalation part of the study will be guided by a well-established statistical method/model to estimate the maximum tolerated dose of LJM716 in combination with cetuximab", 
                "measure": "Phase Ib: Number of Total Dose-limiting Toxicity (DLT) During Dose Escalation to Determine Maximum Tolerated Dose (MTD)", 
                "safety_issue": "Yes", 
                "time_frame": "35 days"
            }, 
            {
                "description": "Patients with an Objective Overall Response (OOR) were those whose best response to treatment was a complete response (CR) or a partial response (PR) assessed by imaging, as pr RECIST 1.1.", 
                "measure": "Phase II: Percentage of Patients with an Objective Overall Response (OOR) per RECIST 1.1", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02143622"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "This will be assessed by looking at the number of Adverse Events (AEs), serious AEs (SAEs) changes in hematology and chemistry values, vital signs, electrocardiograms (ECGs), dose interruptions, reductions and dose intensity.", 
                "measure": "Safety and tolerability of the LJM716- cetuximab combination", 
                "safety_issue": "Yes", 
                "time_frame": "6 months"
            }, 
            {
                "description": "blood concentration versus time profiles blood PK parameters will be used to characterize the PK profiles of LJM716 and cetuximab concentration when used in combination", 
                "measure": "blood concentration versus time profiles blood PK parameters of LJM716 and cetuximab concentration", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "description": "BOR will be used to further assess the anti-tumor activity of LJM716-cetuximab combination.", 
                "measure": "Best overall response (BOR), per RECIST 1.1", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "description": "Duration of response will be used to further assess the anti-tumor activity of LJM716-cetuximab combination", 
                "measure": "Duration of response (DOR) per RECIST 1.1", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "description": "Overall survival will be used to further assess the anti-tumor activity of LJM716-cetuximab combination", 
                "measure": "Overall survival (OS) per RECIST 1.1", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "description": "Progression free survival will be used to further assess the anti-tumor activity of LJM716-cetuximab combination", 
                "measure": "Progression free survival (PFS) per RECIST 1.1", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }
        ], 
        "source": "Novartis", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Novartis Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2014", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}